Program Collections

The Accelerating Medicines Partnership (AMP) is a public-private collaboration aimed at identifying the genes, proteins, and pathways involved in disease progression and treatment response. Using single-cell technologies and big data tools, researchers develop new therapeutic targets for rheumatoid arthritis, lupus, and other diseases.

The Asthma and Allergic Diseases Cooperative Research Centers (AADCRCs) lead multidisciplinary research on the immunological mechanisms, diagnosis, treatment, and prevention of asthma and allergic diseases. This program is central to NIAID’s efforts to advance understanding and improve therapies for these conditions.

The Autoimmunity Centers of Excellence (ACE) foster collaboration between clinicians and researchers to accelerate autoimmune disease research and therapy development. This program bridges basic and clinical research to translate discoveries into effective treatments.

Advancing Clinical Therapeutics Globally (ACTG) supports the world's largest network of clinical and translational investigators conducting therapeutic research, with a focus on resource-limited settings. These experts lead HIV/AIDS clinical trials, treatment programs, and training initiatives to improve outcomes worldwide.

The Atopic Dermatitis Research Network (ADRN) is a consortium of academic medical centers studying skin infections associated with atopic dermatitis. The network conducts clinical research to improve understanding and treatment of these infections.

The Antiviral Drug Discovery (AViDD) Centers conduct multidisciplinary research to develop antiviral drugs for COVID-19 and other high-risk virus families with pandemic potential. Their focus is on creating innovative treatments, including outpatient therapeutics, to strengthen pandemic preparedness.

The Center for Advanced Tissue Imaging (CAT-I) is a collaborative effort between NIAID and NCI to develop advanced imaging methods for high-dimensional tissue analysis. The center supports interdisciplinary studies to enhance the visualization of complex biological systems.

Childhood Asthma in Urban Settings (CAUSE) studies how environmental factors, allergens, and genetics influence asthma development and severity in children. The network aims to improve asthma prevention and treatment strategies in urban communities.

The Cooperative Centers on Human Immunology (CCHI) supports research aimed at translating immunological discoveries into clinical applications for infectious and immune-mediated diseases. The program investigates immune system function across diverse populations, including transplant recipients and pregnant women.

The Centers of Excellence for Influenza Research and Response (CEIRR) is an international research network that studies the transmission and pathogenesis of influenza while providing critical infrastructure for outbreak responses. The program builds on prior influenza research initiatives to enhance global preparedness strategies.

The Centers for AIDS Research (CFAR) provides administrative and research support to enhance and coordinate high-quality HIV/AIDS research. This program fosters collaboration across disciplines to advance scientific discoveries and improve patient outcomes.

The Center for HIV/AIDS Vaccine Development (CHAVD) consists of two research consortia focused on developing and refining HIV immunogens and regimens that induce broadly neutralizing antibody (bNAb) responses. The goal is to advance clinical testing for HIV vaccine development.

The Centers for HIV Structural Biology (CHIV-SB) use structural biology, biochemistry, and cell biology to map the three-dimensional structures of HIV proteins, nucleic acids, and their interactions with cellular components. This research provides insights into HIV mechanisms and identifies potential targets for new therapies and preventive vaccines.

The Clinical Islet Transplantation Consortium (CITC) is a research network conducting studies on islet transplantation for patients with type 1 diabetes. The program aims to improve transplantation techniques and long-term outcomes for individuals with the disease.

Collaborative Influenza Vaccine Innovation Centers (CIVICs) is a network of research centers working collaboratively to develop next-generation influenza vaccines. Their goal is to create vaccines that provide broader, longer-lasting protection against influenza viruses.

The Medical Countermeasures against Radiation Consortium (CMCRC) is a network of research centers developing medical countermeasures for radiological and nuclear emergencies. The program focuses on creating effective treatments applicable to all civilian populations.

The Consortium for Food Allergy Research (CoFAR) conducts clinical research to improve understanding, diagnosis, and treatment of food allergies. The consortium focuses on advancing therapies to prevent and manage allergic reactions.

The Centers for Research in Emerging Infectious Diseases (CREID) Network is a global consortium of research centers focused on studying emerging and re-emerging infectious diseases in regions prone to outbreaks. These centers conduct surveillance, research, and response efforts to better mitigate future infectious disease threats.

Clinical Trials in Organ Transplantation in Children (CTOT-C) addresses challenges in pediatric organ transplantation through collaborative clinical trials. The program builds on previous NIAID pediatric transplantation research to improve long-term transplant outcomes.

The Division of AIDS (DAIDS) leads the national HIV/AIDS research agenda, supporting a global portfolio to advance biological knowledge and treatment of HIV/AIDS and related co-infections. The division funds studies to develop new therapies, vaccines, and prevention strategies.

The NIAID Genomic Centers for Infectious Diseases (GCID) advances understanding of microbial biology, pathogenesis, and host interactions by providing high-throughput sequencing and other genomic technologies. These centers support diverse genomic research to improve infectious disease prevention and treatment.

The Human Immunology Project Consortium (HIPC) is a research network that characterizes the diverse states of the human immune system using advanced analytic tools. Researchers study immune responses before and after infection, vaccination, or treatment to improve disease understanding and intervention strategies.

The HLA (human leukocyte antigen) Region Genetics in Immune-Mediated Diseases Consortium (HLA RGIMDC) studies how genetic variations in the HLA gene region and killer immunoglobulin-like receptor gene family influence immune-mediated diseases. The consortium aims to improve understanding of disease mechanisms and potential therapeutic targets.

The HIV Prevention Trials Network (HPTN) conducts clinical trials to evaluate the safety and efficacy of non-vaccine HIV prevention strategies. Research areas include pre-exposure prophylaxis, behavioral interventions, and novel biomedical approaches to reduce HIV transmission.

The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded collaboration for evaluating HIV vaccines. In addition to advancing HIV vaccine research, the network contributes to studies on tuberculosis, COVID-19, and immunology.

The International Centers of Excellence for Malaria Research (ICEMR) is a global network of research centers in malaria-endemic regions dedicated to understanding, controlling, and preventing malaria. These centers generate critical knowledge and tools to combat malaria effectively.

The International Epidemiology Databases to Evaluate AIDS (IeDEA) Cohort Consortium is a global research consortium that harmonizes and pools HIV/AIDS data from seven international regions. This collaborative effort supports large-scale epidemiological studies to improve HIV/AIDS treatment and prevention strategies worldwide.

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is a global network conducting clinical trials to prevent and treat HIV in infants, children, adolescents, and pregnant or postpartum women. The network brings together investigators, institutions, and community representatives to advance HIV research and care.

The Immune Mechanisms of Protection Against Mycobacterium tuberculosis Centers (IMPAc-TB) investigates immune responses required to protect against Mycobacterium tuberculosis infection. The program aims to advance vaccine and therapeutic development by identifying key protective mechanisms.

The Immunity in Neonates and Infants (INI) Program supports research on immune system development during the first year of life. It encourages innovative studies using human infant tissues, cells, or animal models to define key pathways shaping neonatal and infant immunity.

The Immune Tolerance Network (ITN) is an international research consortium focused on developing therapies that promote immune tolerance for treating immune-mediated diseases. The network conducts clinical studies on immune tolerance in asthma, allergies, and other disorders.

The Martin Delaney Collaboratories (MDC) for HIV Cure Research is NIH’s flagship program for HIV cure research, fostering collaboration among basic, applied, and clinical researchers. The program focuses on understanding HIV persistence and developing potential curative strategies.

The U.S. Military HIV Research Program (MHRP) focuses on HIV vaccine development, prevention, disease surveillance, and treatment to protect U.S. military personnel. The program also contributes to global HIV research and public health initiatives.

The Microbicide Trials Network (MTN) is an NIAID-funded global research network focused on preventing the sexual transmission of HIV. The network conducts clinical trials to evaluate microbicides and other biomedical prevention strategies.

The National Biosafety and Biocontainment Training Program (NBBTP)/Intramural Research Training Award (IRTA) Fellowship trains professionals to support high-containment research environments by developing expertise in biosafety, biocontainment, regulatory compliance, and facility management. The program prepares fellows to address challenges in conducting research in high-risk infectious disease laboratories.

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide high-containment (BSL4/3/2 and BSL3/2) facilities for research on biodefense and emerging infectious diseases. These laboratories support national preparedness and response efforts for infectious disease threats.

PREMISE (Pandemic REsponse REpository through Microbial and Immune Surveillance and Epidemiology), led by the NIAID Vaccine Research Center, supports pandemic preparedness by conducting virologic and immunologic screening. Through a network of investigators, the program detects immune responses to pathogens with pandemic potential.

SARS-CoV-2 Assessment of Viral Evolution (SAVE) provides real-time risk assessment of emerging SARS-CoV-2 mutations that may impact transmissibility and virulence. This program supports the SARS-CoV-2 Interagency Group (SIG) by evaluating viral evolution and informing public health responses.

The Systems Approach to Immunity and Inflammation (SysAII) Program combines forward genetic screens in mice with systems-level analysis to uncover key immune regulatory genes and signaling pathways. Findings are validated in human cells and tissues to improve understanding of immune and inflammatory processes.

The NIAID/Division of Microbiology and Infectious Diseases (DMID) Systems Biology Consortium for Infectious Diseases brings together interdisciplinary scientists across microbiology, immunology, infectious diseases, computational biology, and advanced data science. Their collaborative work integrates experimental and computational approaches, including machine learning and mathematical modeling.

The Tuberculosis Research Units (TBRU-N) is a collaborative research network aimed at understanding Mycobacterium tuberculosis (Mtb)-host interactions. The program advances tuberculosis research to improve diagnostics, treatments, and vaccine development.

T Cell Reagent Research for the Study of Allergic Diseases (TCRR-SAD) advances the identification, characterization, and validation of novel T-cell epitopes in food allergens and aeroallergens. This research enhances understanding of allergic disease mechanisms and informs therapeutic development.

The United States Immunodeficiency Network (USIDNET) is a NIH-funded research program dedicated to advancing scientific knowledge on primary immunodeficiency (PI) diseases. The network collects patient data and supports research to improve diagnosis and treatment.

The United States President’s Emergency Plan for AIDS Relief (PEPFAR) is a U.S. government initiative dedicated to combating HIV/AIDS worldwide through treatment, prevention, and care programs. It represents the largest international commitment by any nation to fight a single disease.